Alterity Therapeutics Ltd
ATHE Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.14
KIRA · Stoqly’s AI analyst, in plain words
- Alterity Therapeutics Ltd had $1.2M of revenue in fiscal 2026, down 77.8% on the year before. Over five years, revenue changed −19.1% a year on average.
- Alterity Therapeutics Ltd lost $15.9M in fiscal 2026.
- Free cash flow was −$15.3M in fiscal 2026, −1,312.0% of revenue.
Market cap
$37.5M
P/E
—
Revenue
$1.2M
Net income
−$15.9M
Free cash flow
−$15.3M
Operating margin
—
Alterity Therapeutics Ltd in 30 seconds · fiscal 2026
Are sales growing?
−77.8%
No. Sales fell 77.8% last year.
Does it make a profit?
−1,363.1%
No. It lost money last year.
Does profit turn into cash?
−1,312.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
What Alterity Therapeutics Ltd does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 20-F · Aug 28, 2026
- Legal name
- ALTERITY THERAPEUTICS LTD
- CIK
- 0001131343
Alterity Therapeutics Ltd · ATHE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.7M | $2.6M | $2.8M | $5.2M | $1.2M |
| Revenue growth | 10.6% | −28.9% | 6.3% | 86.2% | −77.8% |
| Net interest income | — | — | $0.2M | $0.3M | $1.2M |
| Net income | $9.3M | $9.3M | −$12.5M | −$7.9M | −$15.9M |
| Net margin | 250.6% | 351.1% | −446.0% | −150.2% | −1,363.1% |
| Diluted EPS | −$4.61 | −$4.60 | −$4.09 | −$1.48 | — |
| Cash | |||||
| Cash from operations | −$9.0M | −$13.5M | −$8.3M | −$7.4M | −$15.3M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$9.0M | −$13.5M | −$8.3M | −$7.4M | −$15.3M |
| FCF margin | −242.4% | −509.6% | −294.1% | −141.6% | −1,312.0% |
| Share count change | 41.8% | 0.9% | 50.3% | 75.3% | −96.7% |
| Debt and strength | |||||
| Cash and short-term investments | $23.9M | $10.5M | $8.4M | $21.7M | $25.7M |
| Shareholders' equity | $24.4M | −$129M | −$143M | −$148M | $29.4M |
| Current ratio | 7.1x | 6.2x | 3.5x | 13.0x | 14.5x |
| Returns and quality | |||||
| Return on equity | 39.5% | — | — | — | — |
| Return on tangible equity | 38.2% | — | — | — | −53.9% |
| Piotroski F-score | 1 | 3 | 2 | 3 | 3 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alterity Therapeutics Ltd · ATHE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.14 a share, the company is worth $37.5M.
Source: SEC EDGAR XBRL filings (CIK 0001131343). Data updated October 24, 2026. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.